KLAS-TELECOM
Klas Telecom announced today they will supply the TRX Connected Transportation Platform to global engineering house Ikusi for a project to upgrade the passenger information systems onboard Renfe train fleets. Under a Memorandum of Understanding, Klas Telecom’s TRX platform will provide an onboard Wi-Fi infrastructure that improves connectivity to and within the train so that passengers have a better user experience accessing the mobile information and services they need. Klas Telecom and Ikusi have enjoyed a longstanding relationship in which they have worked together to design and develop bespoke solutions to deliver the exacting requirements stipulated by Ikusi’s railway customers.
Ikusi selected Klas Telecom’s TRX R6 as the key component of the onboard passenger Wi-Fi system. The TRX R6 will deliver reliable, high-bandwidth and low-latency connectivity to the train. Another key component of the passenger Wi-Fi system is the software-defined wide area network (SDWAN) feature of the TRX operating system, KlasOS. The KlasOS SDWAN aggregates WAN links and manages multiple wireless bearers in order to provide the train both higher throughput and availability of the offboard WAN link. Klas Telecom’s advanced SDWAN technology leverages any available Internet connection, whether in-station Wi-Fi or 3G/4G LTE connections. The KlasOS SDWAN feature seamlessly routes traffic over uncongested links to ensure that passengers stay connected at all times whether checking e-mails, updating social media, remote working over VPN or making a video call.
“Our partnership with Klas Telecom has gone from strength to strength in recent years,” Ikusi Director of Railway Solutions José Morales said. “We can count on their competence to develop the most appropriate solution to meet the project requirements every time. This Memorandum of Understanding ensures that Ikusi continues to work closer than ever to Klas Telecom, ultimately resulting in greater passenger satisfaction for our customers.”
Brendan Fleming, Klas Telecom Director of Business Development for Transportation, added, “Working with a partner like Ikusi allows us to demonstrate what we do best: developing and supplying the latest cutting-edge technology as part of an onboard Wi-Fi solution, allowing the end customer to provide an optimum passenger experience.”
You can view Klas Telecom’s TRX platform this week at InnoTrans 2018 in Hall 7.1B at Messe Berlin.
More About Klas Telecom
With a background in satellite communications, Klas Telecom is an engineering and design company with over 25 years of experience developing innovative communications solutions for the network edge. Klas Telecom delivers connectivity to communications black spots and austere environments where low size, weight, power and ruggedization are required. The company specializes in integrating enterprise networking capabilities from global IT leaders with in-house hardware and software platforms designed and proven against the most stringent environmental requirements. With over 80% of the company dedicated to technology development, Klas Telecom is able to stay on the forefront of the deployable communications technology. Klas Telecom operates in the public safety, transportation and U.S. and international defense markets. The company employs staff across four offices located in Washington, DC; Herndon, VA; Tampa, FL; and Dublin, Ireland. www.klastelecom.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005821/en/
Contact:
Klas Telecom Carrie Sarver Hall | VP of Marketing and Communications 202-288-6342 carrie.hall@klastelecom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom